<p>Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis</p>Katsuaki Ogushi, Shin Maeda, Taito Fukushima et al.|Clinical and Experimental Gastroenterology|2020Cited by 55
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysisMakoto Chuma, Shin Maeda, Haruki Uojima et al.|Hepatology Research|2021Cited by 50
Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort studyHisashi Hidaka, Wasaburo Koizumi, Haruki Uojima et al.|Hepatology Research|2020Cited by 31
Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of HepatologyNahoko Kikuchi, Wasaburo Koizumi, Haruki Uojima et al.|Hepatology Research|2021Cited by 24
A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinomaShuichiro Iwasaki, Wasaburo Koizumi, Hisashi Hidaka et al.|Clinical Journal of Gastroenterology|2021Cited by 14